PNC Financial Services Group
VRPX

PNC Financial Services Group’s Virpax Pharmaceuticals, Inc. Common Stock VRPX Stock Holding History

PNC Financial Services Group’s Portfolio VRPX Stock Details VRPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-404
Closed -$32.3K – 4857
2023
Q4 		$32.3K Hold
404
– – ﹤0.01% 3181
2023
Q3 		$80.7K Hold
404
– – ﹤0.01% 2705
2023
Q2 		$109K Hold
404
– – ﹤0.01% 2595
2023
Q1 		$79.2K Hold
404
– – ﹤0.01% 2711
2022
Q4 		$62.7K Hold
404
– – ﹤0.01% 2842
2022
Q3 		$120K Hold
404
– – ﹤0.01% 2416
2022
Q2 		$169K Buy
404
+303
+300% +$124K ﹤0.01% 2254
2022
Q1 		$56K Hold
101
– – ﹤0.01% 3045
2021
Q4 		$86K Buy
+101
New +$104K ﹤0.01% 2786

Other funds holding VRPX

TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
SRCM
Signature Resources Capital Management Newport Beach, California $254M AUM 26.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return

PNC Financial Services Group's VRPX Position: Q1 2024 in Review

PNC Financial Services Group sold out of Virpax Pharmaceuticals, Inc. Common Stock (VRPX) in Q1 2024, closing a stake of 404 shares — an estimated $32.3K sold.

PNC Financial Services Group first reported a position in VRPX in Q4 2021 and held it in 9 quarters. The position peaked at $169K in Q2 2022. 3 funds tracked by Wall St. Rank hold VRPX as of Q1 2024.

  • PNC Financial Services Group reported no remaining Virpax Pharmaceuticals, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • PNC Financial Services Group sold 404 Virpax Pharmaceuticals, Inc. Common Stock shares in Q1 2024, an estimated $32.3K.
  • PNC Financial Services Group first reported a position in Virpax Pharmaceuticals, Inc. Common Stock in Q4 2021 and held it in 9 quarters.
  • PNC Financial Services Group's Virpax Pharmaceuticals, Inc. Common Stock position peaked at $169K in Q2 2022.
  • 3 funds tracked by Wall St. Rank held Virpax Pharmaceuticals, Inc. Common Stock as of Q1 2024.

Based on PNC Financial Services Group's 13F filing for Q1 2024, filed 10 May 2024.